REVIEW article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1617305
This article is part of the Research TopicMolecular Biomarkers of Cardiometabolic Disease - Volume IIView all 13 articles
Energy Metabolism in Cardiovascular Diseases: Unlocking the Hidden Powerhouse of Cardiac Pathophysiology
Provisionally accepted
Mengnan Liu1*
Li Chen1
Mingtai Chen2
Xinrui Yang1Yuanli Hu1Caiwei Qiu1Youyou Fu1Xiaoyu Lan1Gang Luo1*
Qiuyu Liu3*- 1Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
- 2Shenzhen Traditional Chinese Medicine Hospital, Shenzhen ，Guangdong, China
- 3Southwest Medical University, Luzhou, Sichuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, yet their pathogenesis has not been fully elucidated, particularly regarding the role of abnormal energy metabolism. Major outstanding questions pertain to the dynamic regulation of metabolic reprogramming and its complex interplay with mitochondrial dysfunctio. Previous studies have demonstrated that the heart, as a high-energy-demand organ, relies on the dynamic equilibrium of substrates such as fatty acid (FA) and glucose to sustain adenosine triphosphate (ATP) production. Metabolic disturbances-characterized by suppressed FA oxidation and aberrant activation of glycolysis-directly contribute to the pathological progression of various CVDs, including heart failure (HF), atherosclerosis, and myocardial infarction(MI), through mechanisms involving oxidative stress, inflammatory responses, and an energy crisis. This review systematically examines the core pathways of cardiac energy metabolism (e.g., mitochondrial oxidative phosphorylation (OXPHOS), regulation of glucose and lipid metabolism) and their dysregulation in disease states, while evaluating intervention strategies targeting metabolic pathways, such as mitochondrial function enhancement and substrate utilization modulation. Future research directions emphasize the integration of metabolomics with clinical translational studies to comprehensively decipher the multidimensional regulation of metabolic networks, thereby facilitating the development of novel precision therapeutic targets.
Keywords: Cardiovascular diseases (CVDs), Energy Metabolism, metabolic reprogramming, Mitochondrial dysfunction, Precision therapeutic targets
Received: 24 Apr 2025; Accepted: 16 May 2025.
Copyright: © 2025 Liu, Chen, Chen, Yang, Hu, Qiu, Fu, Lan, Luo and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mengnan Liu, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
Gang Luo, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China
Qiuyu Liu, Southwest Medical University, Luzhou, Sichuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.